Showing 1 - 6 results of 6 for search 'Keri Yang', query time: 0.02s Refine Results
  1. 1
    P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

    P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (U... by Bijal Shah, Mei Xue, Keri Yang, Sizhu (Tom) Liu, Boxiong Tang

    Published 2023-08-01
    Get full text
    Article
  2. 2
    P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

    P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) by Catherine Thieblemont, Kaijun Wang, Sam Keeping, Ina Zhang, Keri Yang, Boxiong Tang, Leyla Mohseninejad

    Published 2023-08-01
    Get full text
    Article
  3. 3
    P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

    P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) by Catherine Thieblemont, Kaijun Wang, Sam Keeping, Ina Zhang, Keri Yang, Boxiong Tang, Leyla Mohseninejad

    Published 2023-08-01
    Get full text
    Article
  4. 4
    P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

    P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) by Barbara Eichhorst, Nicole Lamanna, Susan O’brien, Constantine Tam, Lugui Qiu, Keri Yang, Ken Wu, Tommi Salmi, Gisoo Barnes, Jennifer R. Brown

    Published 2023-08-01
    Get full text
    Article
  5. 5
    A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

    A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (C... by Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han, Xiaowei Zhang, Lindsey Roeker, Nicola Wallis, Jennifer C. Stern, Eric Hedrick, Jane Huang, Jeff P. Sharman

    Published 2023-02-01
    Get full text
    Article
  6. 6
    P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP

    P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN... by Alessandra Tedeschi, Constantine Tam, Roger Owen, Christian Buske, Véronique Leblond, Meletios A. Dimopoulos, Ramón García-Sanz, Jorge Castillo, Judith Trotman, Steven Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Chan, Aileen Cohen, Jingjing Yan Schneider, Gisoo Barnes

    Published 2023-08-01
    Get full text
    Article

Search Tools: